What is the appropriate next step for a patient with elevated fecal calprotectin but normal colonoscopy and normal capsule endoscopy (pill cam)?

Management of Elevated Fecal Calprotectin with Normal Colonoscopy and Capsule Endoscopy

When both colonoscopy and capsule endoscopy are normal despite elevated fecal calprotectin, repeat the calprotectin measurement in 3-6 months and exclude non-IBD causes of elevation, rather than pursuing further invasive testing or empiric treatment escalation. 1

Initial Assessment and Exclusion of Alternative Causes

Before attributing the elevated calprotectin to occult inflammatory bowel disease, systematically exclude other common causes:

• Test for infectious etiologies, particularly Clostridioides difficile and other enteric pathogens, as these can significantly elevate calprotectin and mimic IBD 2, 1
• Review medication history for NSAIDs, which can cause enteropathy and elevate calprotectin without visible lesions 3
• Consider Helicobacter pylori infection, which is associated with significant calprotectin elevations (mean 241.2 µg/g vs 88.1 µg/g in uninfected patients) 4
• Evaluate for celiac disease and microscopic colitis, both identified in patients with elevated calprotectin but normal endoscopy 3

Understanding the Clinical Context

The diagnostic yield and next steps depend critically on your patient's symptom status:

In Symptomatic Patients

For patients with ongoing GI symptoms:

• A normal colonoscopy and capsule endoscopy effectively rules out significant small bowel Crohn's disease, as capsule endoscopy has superior diagnostic yield compared to MR enterography for detecting early small bowel lesions 3
• In one large series of 320 patients with elevated calprotectin and normal colonoscopy who underwent capsule endoscopy, 79.4% had small bowel Crohn's disease identified, but your patient has already had this excluded 3
• The false-negative rate for capsule endoscopy in this setting is low, particularly when calprotectin is markedly elevated 5, 6

In Asymptomatic Patients

For patients in symptomatic remission:

• 20-26% of patients with confirmed endoscopic remission may still have elevated calprotectin, representing false-positive results 1
• The AGA guidelines specifically address this scenario: repeat biomarker measurement in 3-6 months is an acceptable alternative to immediate additional testing 7, 1

Recommended Management Algorithm

Step 1: Repeat Calprotectin in 3-6 Months

• This is the preferred next step when initial endoscopic evaluation (colonoscopy + capsule endoscopy) is normal 1
• If calprotectin normalizes (<150 µg/g), no further investigation is needed 7
• If calprotectin remains elevated or increases, proceed to Step 2 1

Step 2: Consider Cross-Sectional Imaging

If calprotectin remains persistently elevated after 3-6 months:

• MR enterography may detect transmural inflammation or complications not visible on mucosal imaging, though capsule endoscopy is more sensitive for mucosal lesions 3
• This is particularly relevant if symptoms develop or worsen during the observation period 7

Step 3: Clinical Monitoring Without Treatment Escalation

Do not initiate empiric IBD therapy in the absence of endoscopic confirmation of disease:

• The AGA explicitly recommends against empiric treatment adjustment based solely on elevated biomarkers without endoscopic confirmation 7
• In patients with normal endoscopy (colonoscopy), elevated calprotectin was not associated with increased risk of significant GI disease over 3-year follow-up 8

Important Caveats and Pitfalls

Specificity Limitations

• Calprotectin has high sensitivity (78-96%) but poor specificity (23-67%) for small bowel inflammation when colonoscopy is normal 5, 9
• At a cutoff of 50 µg/g: sensitivity 96%, specificity 23% 5
• At a cutoff of 100 µg/g: sensitivity 75%, specificity 67% 5
• This means many patients with elevated calprotectin will have normal findings on comprehensive endoscopic evaluation 8, 9

Location-Specific Correlation

• Calprotectin correlates poorly with proximal small bowel inflammation (first tertile), showing significant correlation only with second and third tertile (more distal) small bowel disease 10
• If your patient has very proximal small bowel disease, capsule endoscopy may have missed subtle findings, though this is uncommon 10

When to Reconsider the Diagnosis

Consider that the patient may not have IBD if:

• Calprotectin normalizes spontaneously on repeat testing 1
• No symptoms develop over 6-12 months of observation 8
• Alternative explanations (NSAIDs, infection, other causes) are identified 3, 4

Long-Term Monitoring Strategy

For patients with persistently elevated calprotectin but normal endoscopy:

• Monitor with patient-reported outcomes and repeat calprotectin every 6-12 months 2, 1
• Perform repeat endoscopic evaluation only if symptoms develop or calprotectin significantly increases (e.g., >250-300 µg/g) 7, 1
• Recognize that up to 50% of patients initially presenting with isolated findings may develop more extensive disease over time, warranting continued surveillance 2